| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Case Report |
| Article Title |
Multiple pseudoprogressions during ongoing immunotherapy-based treatment of advanced gastric neuroendocrine carcinoma: A case report and review of literature
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Yan-Hua Mou, Juan Zhang, Hui Shen, Jing Yu, Lan Han, Hui Li and Qing-Feng Li |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Wu Jieping Medical Foundation |
320.6750.2021-02-113 |
|
| Corresponding Author |
Qing-Feng Li, MD, Professor, Department of Oncology, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, No. 136 Jingzhou Road, Xiangyang 441021, Hubei Province, China. liqfeng@hbuas.edu.cn |
| Key Words |
Gastric neuroendocrine carcinomas; Pseudoprogression; Immunotherapy; Teprotumumab; Case report |
| Core Tip |
Neuroendocrine carcinomas (NECs) are generally considered highly malignant, characterized by rapid growth, a high metastasis rate, and poor prognosis, and their malignancy is much higher than that of gastric adenocarcinoma. Immune checkpoint inhibitors are a new type of immunotherapy drugs used in cancer treatment. However, the differences in clinical response and drug resistance pose significant challenges in immunotherapy. This article aims to report an extremely rare case of NEC, in which two significant pseudoprogression (PsP) occurred during treatment with PD-1 inhibitors combined with tyrosine kinase inhibitors. More rarely, this case had two PsP in the same organ under the same treatment plan. Besides, we mainly introduced the existing research on the possible mechanisms, timepoint, clinical manifestations, biomarkers, and medical imaging techniques associated with PsP. |
| Publish Date |
2025-02-14 10:33 |
| Citation |
<p>Mou YH, Zhang J, Shen H, Yu J, Han L, Li H, Li QF. Multiple pseudoprogressions during ongoing immunotherapy-based treatment of advanced gastric neuroendocrine carcinoma: A case report and review of literature. <i>World J Gastrointest Oncol</i> 2025; 17(3): 102804</p> |
| URL |
https://www.wjgnet.com/1948-5204/full/v17/i3/102804.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v17.i3.102804 |
